IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · IEX Real-Time Price · USD
40.89
-0.22 (-0.54%)
Jul 19, 2024, 4:00 PM EDT - Market closed
IDEAYA Biosciences Employees
IDEAYA Biosciences had 124 employees as of December 31, 2023. The number of employees increased by 21 or 20.39% compared to the previous year.
Employees
124
Change (1Y)
21
Growth (1Y)
20.39%
Revenue / Employee
$125,032
Profits / Employee
-$1,039,460
Market Cap
3.44B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 124 | 21 | 20.39% |
Dec 31, 2022 | 103 | 22 | 27.16% |
Dec 31, 2021 | 81 | 19 | 30.65% |
Dec 31, 2020 | 62 | 4 | 6.90% |
Mar 31, 2019 | 58 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Neogen | 2,640 |
HUTCHMED (China) | 1,988 |
Inari Medical | 1,300 |
Axonics | 797 |
PROCEPT BioRobotics | 626 |
Arrowhead Pharmaceuticals | 525 |
Corcept Therapeutics | 352 |
TG Therapeutics | 264 |
IDYA News
- 10 days ago - IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares - PRNewsWire
- 12 days ago - IDEAYA Announces Pricing of Public Offering - PRNewsWire
- 12 days ago - IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants - PRNewsWire
- 13 days ago - IDEAYA Biosciences Soars on Cancer Drug Study Results - Investopedia
- 13 days ago - IDEAYA Biosciences Highlights 'Encouraging' Preliminary Efficacy, Safety Profile For Patients With Hard-To-Treat Cancer - Benzinga
- 14 days ago - IDEAYA Announces Positive Interim Phase 2 Monotherapy Expansion Data for IDE397 a Potential First-in-Class MAT2A Inhibitor in MTAP-Deletion Urothelial and Lung Cancer - PRNewsWire
- 16 days ago - IDEAYA Announces Investor Webcast to Report Clinical Data Update for IDE397 Phase 2 Monotherapy Expansion Dose in MTAP-Deletion Urothelial and Lung Cancer on Monday, July 8, 2024 - PRNewsWire
- 24 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire